Table 3 Univariate and multivariate analyses of overall survival in patients with all types of AML, for the LSC- DNM gene-sets

GSE14468 (n = 518)

Univariate model

3 DNM fGSs vs 4 control fGSs

0.7

0.55-0.84

0.00043***

ELN_RiskFavorable vs. Adverse

0.3

0.20-0.40

2.15E-13***

complex vs. others

2.2

1.50-3.16

0.000024***

7q vs. others

2.1

1.45-2.97

0.000051***

ELN_RiskIntermediate-II vs. Adverse

0.5

0.36-0.70

0.000053***

Age group, years (≥60 vs. <60)

1.7

1.29-2.28

0.00016***

3q vs. others

2.1

1.32-3.42

0.0015**

ELN_RiskIntermediate-I vs. Adverse

0.6

0.46-0.86

0.0035**

inv16 vs. others

0.5

0.32-0.83

0.0057**

cebpa mutation vs. others

0.6

0.67-0.95

0.028*

Multivariate model

3 DNM fGSs vs 4 control fGSs

0.7

0.60-0.91

0.0050**

Age group, years (≥60 vs. <60)

1.7

1.26-2.29

0.00046***

ELN_RiskFavorable vs. Adverse

0.4

0.26-0.76

0.0034**

complex vs. others

1.6

0.96-2.58

0.07.

ELN_RiskIntermediate-II vs. Adverse

0.7

0.43-1.23

0.23

7q vs. others

1.3

0.82-2.09

0.26

3q vs. others

1.3

0.71-2.27

0.42

inv16 vs. others

0.8

0.47-1.39

0.44

cebpa mutation vs. others

0.9

0.53-1.45

0.61

ELN_RiskIntermediate-I vs. Adver

0.9

0.53-1.48

0.65

TCGA (n = 197)

Univariate model

3 DNM fGSs vs 4 control fGSs

0.46

0.32-0.64

4.66E-06***

Age group, years (≥60 vs. <60)

3.02

2.16-4.21

9.94E-12***

gender

0.88

0.64-1.22

0.44

normal_karyotype vs. others

1.12

0.81-1.55

0.50

BM Blast(>50 vs. <=50)

0.88

0.60-1.30

0.53

Multivariate mode

3 DNM fGSs vs 4 control fGSs

0.60

0.42-0.86

0.0058**

Age group, years (≥60 vs. <60)

2.59

1.83-3.67

8.8E-08***

GSE12417 (n = 242)

Univariate model

3 DNM fGSs vs 4 control fGSs

0.60

0.43-0.83

0.0021**

Age group, years (≥60 vs. <60)

1.63

1.18-2.26

0.0029**

Multivariate model

3 DNM fGSs vs 4 control fGSs

0.60

0.43-0.83

0.0021**

Age group, years (≥60 vs. <60)

1.49

1.07-2.07

0.018*